United States securities and exchange commission logo





                             November 24, 2021

       David Mehalick
       President and Chief Executive Officer
       Coeptis Therapeutics, Inc.
       105 Bradford Rd., Suite 420
       Wexford, Pennsylvania 15090

                                                        Re: Coeptis
Therapeutics, Inc.
                                                            Offering Statement
on Form 1-A
                                                            Filed November 18,
2021
                                                            File No. 024-11719

       Dear Mr. Mehalick:

                                                        This is to advise you
that we do not intend to review your offering statement.

               We will consider qualifying your offering statement at your
request. If a participant in
       your offering is required to clear its compensation arrangements with
FINRA, please have
       FINRA advise us that it has no objections to the compensation
arrangements prior to
       qualification.

               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff. We also remind you that, following qualification of
your Form 1-A, Rule 257
       of Regulation A requires you to file periodic and current reports,
including a Form 1-K which
       will be due within 120 calendar days after the end of the fiscal year
covered by the report.

                                                        Please contact Joshua
Gorsky at (202) 551-7836 with any questions.




                             Sincerely,


                             Division of Corporation Finance

                             Office of Life Sciences